Loading…
← CockpitCompetitor Analysis › CSTL Castle Biosciences, Inc.Open in the cockpit ↗

Castle Biosciences, Inc.CSTLCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.

Momentum leader 91
Mkt cap
$1.03B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$15.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.2 pp
WACC 9.9%
Hurdle
+17 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$33.38
1D+1.2%
1W-1.8%
1M+0.7%
3M+1.4%
6M+66.7%
YTD-14.2%
1Y-1.7%
ATR %5.5%
Beta1.10
52w lowhigh24.6% off high

What Castle Biosciences does

Genomic diagnostics company making tests that predict recurrence risk for skin cancers and other dermatologic and eye conditions.

Is paid per test by Medicare and private insurers rather than by the doctors who order them, so coverage decisions and the share of claims actually reimbursed matter as much as test volume. The melanoma and skin-cancer tests carry the business, with newer tests in other conditions still being established.

Products and services

  • DecisionDx-Melanoma
  • DecisionDx-SCC (squamous cell)
  • DecisionDx-UM (uveal melanoma)
  • Other dermatologic gene-expression tests

Customers

  • Dermatologists
  • Oncologists
  • Ophthalmologists

Where it sits in the supply chain

  • Diagnostics
  • Genomic/molecular diagnostics
  • Dermatologic and ocular cancer…

What could go right

  • Test adoption/reimbursement expansion
  • New test launches in adjacent dermatology conditions

What could go wrong

  • Reimbursement/payer coverage risk
  • Niche dermatologic testing market size

Moat: narrow (IP / patents, data). Proprietary gene-expression tests built on clinical outcome data guide treatment decisions, hard to replicate quickly.

Headquarters: Friendswood, Texas · Founded: 2007 · Employees: 883

Named competitors

Castle Biosciences at a glance

Size Castle Biosciences (CSTL) is a United States Health Care company (Medical Specialties) with a market value of $1.03B, the 2216th largest of 3,085 United States companies the cockpit tracks. Shares closed at $33.38 on 18 Nov 2026.

Performance Over six months the shares gained 66.7%, against -7.9% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue grew 9.8% over the last twelve months (peer median +12.3%); the operating margin is -7.4% (peer median 11.6%).

Valuation It trades at 2.1× enterprise value to sales against a peer median of 3.9× (6th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 19.2 points below its cost of capital (9.9% WACC).

Short interest Short interest is 6.8% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026CSTL 163Peer median 92
Six months, rebased to 100: Castle Biosciences against the median of its 20 peers (local-currency closes).

Castle Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$377M$344M$332M$220M$137M
Revenue growth—+4%+51%+60%—
Gross profit$279M$236M$259M$164M$95.4M
EBITDA-$12.1M-$2.04M$24.7M-$55.6M-$80.6M
Net income-$23.0M-$24.2M$18.2M-$57.5M-$67.1M
Free cash flow$3.96M$28.3M$43.2M-$13.8M-$45.9M
Capital expenditure$35.8M$36.0M$28.3M$13.6M$5.63M
Total debt$36.6M$37.0M$26.4M$15.3M$13.3M

Quarterly statements and history in the cockpit →

Castle Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%EUZ6000553010216523300685IRMD300206SIBNCBLL688622301101300143IART214150ATEC77303046SFLDRTSCSTL6-month return →1-month return →
Up and to the right = strong over both horizons. Castle Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×25×50×75×EUZ6000553010216523300685IRMD300206SIBNCBLL688622301101300143SFLCSTLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Castle Biosciences is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%EUZ3010216523300685IRMD300206300143IART21415077303046CSTLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Castle Biosciences is the large dot.

Castle Biosciences competitors and peer comparison

Head to head with its named competitors (CSTL vs MYGN vs VCYT vs NTRA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Castle Biosciences CSTL$1.03B+67%+10%-7%2.1×57.7%
Myriad Genetics MYGN$530M+45%-3%-13%0.8×n/a
Veracyte VCYT$2.06B-43%+18%16%3.0×18.0%
Natera NTRA$42.0B+41%+37%-9%14.1×n/a

How Castle Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Castle Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureCSTLPeer medianRank in peer set
1-month return+0.7%-5.1%9th highest of 21
6-month return+66.7%-7.9%highest of 20
Distance from 52-week high-24.6%-28.9%9th highest of 21
Revenue growth (TTM)+9.8%+12.3%8th lowest of 19
Operating margin-7.4%11.6%5th lowest of 20
EV / Sales2.1×3.9×6th cheapest of 20
Growth the price implies (Req g, 7 yrs)57.7%5.9%most demanding of 14
Growth delivered (Del g)+40.6%+10.4%highest of 14
Hurdle (Req g minus delivered)+17.1 pp-3.4 pp2nd most demanding of 14
ROIC minus cost of capital-19.2 pp+8.0 pp3rd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Mani 7730.TJapan$965M-7%+10%30%3.9×3.3%+13.9%
JINS 3046.TJapan$963M-8%+14%10%1.3×-6.1%+11.7%
Safilo SFL.MIItaly$953M+42%-4%9%0.9×1.3%+4.7%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a

Questions

Who are Castle Biosciences's main competitors?
Named competitors: Myriad Genetics (MYGN), Veracyte (VCYT), Exact Sciences (private or unlisted), Natera (NTRA). The cockpit's measured peer set (industry) also includes Eckert & Ziegler (EUZ.DE), Beijing Wandong Medical Technology (600055.SS), Inno Laser Technology (301021.SZ), PHC (6523.T), Amoy Diagnostics (300685.SZ), IRadimed (IRMD).
Is Castle Biosciences expensive compared with its peers?
On ev / sales it trades at 2.1× against a peer median of 3.9×, 6th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Castle Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +66.7% against -7.9% for the median peer; over one year -1.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.